Evaluation of the effects and plasma concentration of the platelet inhibitor ticagrelor, after crushed and non-crushed intake, after cardiac arrest and after semi-urgent coronary artery bypass surgery
Crushed ticagrelor via nasogastric tube achieved targeted platelet inhibition. Pharmacokinetics aligned with previous studies.EudraCT number: 2013-004191-35; Study protocol code: AGO/2013/011; EC/2014/1061; ClinicalTrial.gov identifier: NCT02341729.
Authors
- Harlinde Peperstraete (ORCID: https://orcid.org/0000-0001-5435-1752)
- Sofie Gevaert (ORCID: https://orcid.org/0000-0002-8721-3003)
- Katrien Devreese (ORCID: https://orcid.org/0000-0002-7559-2579)
- Lukas Duvillier
- Carl Verhaege
Institutions
- Ghent University Hospital (BE)
Publication Details
- Journal
- Acta cardiologica. Supplementum
- Published
- 2024-08-08
- DOI
- https://doi.org/10.1080/00015385.2024.2409521
- Citations
- 1
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.40
Funders
- Universitair Ziekenhuis Gent
- Universiteit Gent